Document is current
Any future updates will be listed below
-
Authors
Xu, Mingfang
Pu, Yu
Jiang, Yuzhu
Liu, Yingda
Feng, Yan
Zhao, Xiaodong
Li, Mengxia
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct04471480 at ClinicalTrials.govDocuments that mention this clinical trial
A phase II study of paclitaxel and carboplatin plus PD-1 inhibitors combined with anlotinib as first-line treatment for advanced esophageal cancer.
https://doi.org/10.1200/jco.2023.41.4_suppl.395
Anlotinib plus camrelizumab and chemotherapy as first-line treatment in patients with advanced esophageal squamous cell carcinoma
https://doi.org/10.1038/s41598-025-06625-2
Tislelizumab combined with anlotinib and chemotherapy (XELOX) in the treatment of advanced gastric carcinoma: Preliminary results of a single-arm, open-label phase I/IIa trial (TALENT study).
https://doi.org/10.1200/jco.2023.41.4_suppl.396
- License Information
-
More Information
Article History
Received: 6 October 2024
Accepted: 10 June 2025
First Online: 1 July 2025
Declarations
:
: The authors declare no competing interests.
